MDK and ovarian carcinoma: The apparent pair of MDK_LRP1 among the three groups suggested that inhibition of the MDK_LRP1 pair might be an effective therapeutic target for ovarian cancer to reduce myeloid inhibitory cell differentiation (MDSCs).